Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Eli Lilly's Selpercatinib Shows Strong Activity in RET Fusion-Positive NSCLC

Eli Lilly's Selpercatinib Shows Strong Activity in RET Fusion-Positive NSCLC

Sep 09, 2019
|
staff reporter

NEW YORK – In the Phase I/II LIBRETTO-001 study, 68 percent of 105 heavily pretreated non-small cell lung cancer patients with RET fusions saw their tumors shrink after treatment with Eli Lilly's investigational RET inhibitor selpercatinib, researchers reported today at the World Conference on Lung Cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

What's Popular?

In Cancer

  1. Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk

  2. TargetCancer Foundation Initiates Precision Medicine Study for Rare Cancers

  3. Daiichi Sankyo, AstraZeneca Partner on Phase I Trial of New Drug Combination for EGFR-Mutated NSCLC

  4. Pfizer to Seek Approval for Lorbrena as First-Line Treatment for ALK-Positive Metastatic Lung Cancer

  5. Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.